Literature DB >> 16393459

Statins and osteoporosis: new role for old drugs.

Satyawan B Jadhav1, Girish Kumar Jain.   

Abstract

Osteoporosis is the most common bone disease, affecting millions of people worldwide and leading to significant morbidity and high expenditure. Most of the current therapies available for its treatment are limited to the prevention or slowing down of bone loss rather than enhancing bone formation. Recent discovery of statins (HMG-CoA reductase inhibitors) as bone anabolic agents has spurred a great deal of interest among both basic and clinical bone researchers. In-vitro and some animal studies suggest that statins increase the bone mass by enhancing bone morphogenetic protein-2 (BMP-2)-mediated osteoblast expression. Although a limited number of case-control studies suggest that statins may have the potential to reduce the risk of fractures by increasing bone formation, other studies have failed to show a benefit in fracture reduction. Randomized, controlled clinical trials are needed to resolve this conflict. One possible reason for the discrepancy in the results of preclinical, as well as clinical, studies is the liver-specific nature of statins. Considering their high liver specificity and low oral bioavailability, distribution of statins to the bone microenvironment in optimum concentration is questionable. To unravel their exact mechanism and confirm beneficial action on bone, statins should reach the bone microenvironment in optimum concentration. Dose optimization and use of novel controlled drug delivery systems may help in increasing the bioavailability and distribution of statins to the bone microenvironment. Discovery of bone-specific statins or their bone-targeted delivery offers great potential in the treatment of osteoporosis. In this review, we have summarized various preclinical and clinical studies of statins and their action on bone. We have also discussed the possible mechanism of action of statins on bone. Finally, the role of drug delivery systems in confirming and assessing the actual potential of statins as anti-osteoporotic agents is highlighted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393459     DOI: 10.1211/jpp.58.1.0002

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  31 in total

1.  Statin use and the risk of colorectal cancer: a population-based case-control study.

Authors:  Meng-Hsuan Cheng; Hui-Fen Chiu; Shu-Chen Ho; Shang-Shyue Tsai; Trong-Neng Wu; Chun-Yuh Yang
Journal:  World J Gastroenterol       Date:  2011-12-21       Impact factor: 5.742

2.  Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species.

Authors:  Ho Jin Moon; Sung Eun Kim; Young Pil Yun; Yu Shik Hwang; Jae Beum Bang; Jae Hong Park; Il Keun Kwon
Journal:  Exp Mol Med       Date:  2011-11-30       Impact factor: 8.718

3.  Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation.

Authors:  Xing Zhong; Ling-ling Xiu; Guo-hong Wei; Yuan-yuan Liu; Lei Su; Xiao-pei Cao; Yan-bing Li; Hai-peng Xiao
Journal:  Acta Pharmacol Sin       Date:  2011-04-18       Impact factor: 6.150

Review 4.  Breaking new ground to build bone.

Authors:  Lauren A Kingsley; John M Chirgwin; Theresa A Guise
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-20       Impact factor: 11.205

5.  Locally applied statins as adjuvants to non-surgical periodontal treatment for chronic periodontitis: a systematic review and meta-analysis.

Authors:  Jonathan Meza-Mauricio; David Soto-Peñaloza; David Peñarrocha-Oltra; Jose Maria Montiel-Company; Daiane Cristina Peruzzo
Journal:  Clin Oral Investig       Date:  2018-06-12       Impact factor: 3.573

6.  Healing of extraction socket following local application of simvastatin: A split mouth prospective study.

Authors:  Aamir Malick Saifi; Girish B Giraddi; Nausheer Ahmed
Journal:  J Oral Biol Craniofac Res       Date:  2017-04-17

7.  Effect of simvastatin on the osteogenetic behavior of alveolar osteoblasts and periodontal ligament cells.

Authors:  Shutai Liu; Kristina Bertl; Hongchen Sun; Zhong-Hao Liu; Oleh Andrukhov; Xiaohui Rausch-Fan
Journal:  Hum Cell       Date:  2012-03-08       Impact factor: 4.174

8.  Melatonin potentiates the anti-tumour effect of pravastatin in rat mammary gland carcinoma model.

Authors:  Peter Orendáš; Peter Kubatka; Bianka Bojková; Monika Kassayová; Karol Kajo; Desanka Výbohová; Peter Kružliak; Martin Péč; Marián Adamkov; Andrea Kapinová; Katarína Adamicová; Vladimíra Sadloňová; Martina Chmelová; Nadežda Stollárová
Journal:  Int J Exp Pathol       Date:  2014-09-30       Impact factor: 1.925

9.  Bone mineral density in prediabetic men.

Authors:  Ju Hee Lee; Yun Hyeong Lee; Kyoung Hye Jung; Min Kyeong Kim; Hye Won Jang; Tae Kyun Kim; Hyun Jin Kim; Young Suk Jo; Minho Shong; Tae Yong Lee; Bon Jeong Ku
Journal:  Korean Diabetes J       Date:  2010-10-31

10.  Comparative impact of systemic delivery of atorvastatin, simvastatin, and lovastatin on bone mineral density of the ovariectomized rats.

Authors:  Mostafa Shahrezaee; Ahmad Oryan; Farshid Bastami; Sepanta Hosseinpour; Mohammad Hossein Shahrezaee; Amir Kamali
Journal:  Endocrine       Date:  2018-01-25       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.